Algeta announces first US Patient Randomized in ALSYMPCA phase III study at Tulane Cancer Center, New Orleans

News   Dec 11, 2009

 
Algeta announces first US Patient Randomized in ALSYMPCA phase III study at Tulane Cancer Center, New Orleans
 
 
 

RELATED ARTICLES

Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell Types

News

New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.

READ MORE

Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization

News

Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..

READ MORE

Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological Aging

News

The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE